Supply/Demand Type 2 Myocardial Infarction

Sandoval, Yader; Smith, Stephen W.; Thordsen, Sarah E.; Apple, Fred S.

doi:10.1016/j.jacc.2014.02.541

Cited by 127 publications

(54 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may be driven by underlying medical comorbidities,16 or perhaps misclassification of a subset of these patients as type 2 MI, when in fact they had type 1 MI 17. To this point, in a recent study of 217 patients with presumed type 2 MI who underwent angiography, 29% had evidence of acute plaque rupture 18.…”

Section: Discussionmentioning

confidence: 99%

Associations Between Cardiac Troponin, Mechanism of Myocardial Injury, and Long‐Term Mortality After Noncardiac Vascular Surgery

Reed

Horr

Young

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundThe time‐sensitive hazard of perioperative cardiac troponin T (cTnT) elevation and whether long‐term mortality differs by mechanism of myocardial injury are poorly understood.Methods and ResultsIn this observational study of 12 882 patients who underwent noncardiac vascular surgery, patients were assessed for cTnT sampling within 96 hours postoperatively. Mortality out to 5‐years was stratified by cTnT level and mechanism of myocardial injury. During a median follow‐up of 26.9 months, there were 2149 (16.7%) deaths. By multivariable Cox proportional hazards analysis, there was a graded increase in mortality with any detectable cTnT compared to <0.01 ng/mL; cTnT 0.01 to 0.029 ng/mL hazard ratio (HR) 1.54 (95% CI 1.18–2.00, P=0.002), 0.03 to 0.099 ng/mL HR 1.86 (95% CI 1.49–2.31, P<0.001), 0.10 to 0.399 ng/mL HR 1.83 (95% CI 1.46–2.31, P<0.001), ≥0.40 ng/mL HR 2.62 (95% CI 2.06–3.32, P<0.001). Mortality for each mechanism of injury was greater than for patients with normal cTnT; baseline cTnT elevation HR 1.71 (95% CI 1.31–2.24; P<0.001), Type 2 myocardial infarction HR 1.88 (95% CI 1.57–2.24; P<0.001), Type 1 MI HR 2.56 (95% CI 2.56, 1.82–3.60; P<0.001). On Kaplan–Meier analysis, long‐term survival did not differ between mechanisms. The hazard of mortality was greatest within the first 10 months postsurgery. Consistent results were obtained in confirmatory propensity‐score matched analyses.ConclusionsAny detectable cTnT ≥0.01 ng/mL is associated with increased long‐term mortality after vascular surgery. This risk is greatest within the first 10 months postoperatively. While short‐term mortality is greatest with Type 1 myocardial infarction, long‐term mortality appears independent of the mechanism of injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Associations Between Cardiac Troponin, Mechanism of Myocardial Injury, and Long‐Term Mortality After Noncardiac Vascular Surgery

Reed

Horr

Young

et al. 2017

JAHA

View full text Add to dashboard Cite

show abstract

“…Кроме того, существует и другой механизм развития ОИМ при ФП. На-пример, эпизоды подобной аритмии с высокой частотой сокращения желудочков могут приво-дить к ОИМ II типа, который характеризуется дисбалансом между потребностью в кислороде и кровоснабжением миокарда и обычно не про-является подъемом сегмента ST [20]. В крупном рандомизированном исследовании ROCKET-AF ОИМ развился у 101 пациента в группе тера-пии ривароксабаном и у 126 -в группе терапии варфарином (0,9 и 1,1% в год соответственно) [8].…”

Section: фибрилляция предсердий и инфаркт миокарда как сопутствующие unclassified

Aspects of antithrombotic therapy in patients with atrial fibrillation and coronary disease

Bockeria¹,

Gafurov²

2018

Ann aritmol

View full text Add to dashboard Cite

“…Baron et al [33] recently compared the clinical characteristics of type 1 MI with those of type 2 and, as expected, the prevalence of eGFR <60 ml/min/1.73 m 2 associated with CKD was about 1.7 times higher in patients with type 2 MI compared with those with type 1 MI. Moreover, Sandoval et al [34] speculate that type 2 MI often occurs in patients with ESKD. Together, these reports are consistent with the specific situation in ESKD where multiple factors are often found to be associated with an imbalance in myocardial oxygen supply and demand.…”

Section: Type 2 MI In Eskd Patientsmentioning

confidence: 99%

Ischemic Heart Disease in Patients with End-Stage Kidney Disease

Tanaka

Joki²,

Hase³

2015

Blood Purif

View full text Add to dashboard Cite

Background: It was recently reported that the severity of coronary and carotid atherosclerosis in patients with end-stage kidney disease (ESKD) has improved over the last two decades. However, the frequency of coronary artery events observed at the initiation of dialysis remains high. Summary: Recently, 5 different clinical types of acute myocardial infarction (MI) were introduced in the third universal definition of MI. Type 2 MI, known as secondary MI, is a more heterogeneous entity, where a condition other than coronary artery narrowing contributes to an acute imbalance in oxygen supply and demand. In patients with chronic kidney disease, it has been demonstrated that type 2 MI is more common than type 1 MI, which is associated with coronary occlusive disease. It is suspected that patients with ESKD also often have type 2 MI. Factors associated with incremental increases in oxygen demand may cause myocardial ischemia in ESKD. Key Messages: Significant epicardial coronary narrowing might not be a necessary precursor of myocardial ischemia in ESKD. To prevent ischemic heart disease and improve prognosis in patients with ESKD, we need to pay attention not only to coronary stenotic lesions, but also to the factors associated with the induction of an imbalance in myocardial oxygen supply and demand.

show abstract

Supply/Demand Type 2 Myocardial Infarction

Cited by 127 publications

References 37 publications

Associations Between Cardiac Troponin, Mechanism of Myocardial Injury, and Long‐Term Mortality After Noncardiac Vascular Surgery

Associations Between Cardiac Troponin, Mechanism of Myocardial Injury, and Long‐Term Mortality After Noncardiac Vascular Surgery

Aspects of antithrombotic therapy in patients with atrial fibrillation and coronary disease

Ischemic Heart Disease in Patients with End-Stage Kidney Disease

Contact Info

Product

Resources

About